Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 5/20 | 0.33 |
| ▸ | ACE | P12821 | 4/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7754112 | 0.80 | PRCP (0.30) | KMT2A | |
| SCHEMBL24940616 | 0.76 | CYP2C9 (0.44) | ALDH1A1 | |
| SCHEMBL1582318 | 0.76 | OPRK1 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14155712 | 0.73 | SIGMAR1 (0.42) | KMT2AALDH1A1 | |
| SCHEMBL17788020 | 0.72 | OPRK1 (0.35) | MEN1KMT2AALDH1A1 | |
| SCHEMBL499847 | 0.72 | MEN1 (0.44) | ACELTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL12028781 | 0.71 | PTPN2 (0.36) | — | |
| SCHEMBL717017 | 0.70 | MEN1 (0.49) | LTA4HMEN1KMT2AALDH1A1 | |
| SCHEMBL24991352 | 0.70 | SLC6A9 (0.36) | SLC6A9 | |
| SCHEMBL24829568 | 0.70 | SLC6A9 (0.36) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100402084-C | Method for detection or quantitative determination of metabolite of fentanyl or metabolite of fentanyl analogues and kit | LANDAUKES LAB CO LTD (GB) | 2008-07-16 | — | — | CN | disclosed |
| EP-1312923-B1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LAB LTD (GB) | 2007-03-28 | — | — | EP | disclosed |
| US-7109310-B2 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LABORATORIES, LTD. (IE) | 2006-09-19 | — | — | US | disclosed |
| US-20030170728-A1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | RANDOX LABORATORIES LIMITED | 2003-09-11 | — | — | US | disclosed |
| EP-1312923-A2 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | Randox Laboratories Ltd. (GB) | 2003-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030170728-A1 | Method and kit for detecting, or determining the quantity of, metabolites of fentanyl and metabolites of fentanyl analogs | OPRK1, KIT, OPRM1 | SLC6A9 4258/4885ACE 1485/4885LTA4H 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.